Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of Antibody Responses After MenACWY or MenC Vaccination in Children
2010-023858-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of menacwy conjugate vaccine in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoints: Immunogenicity Endpoints and Safety and tolerability. Started Jan 2011; status: completed.
02
Drugs
menacwy conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2010-023858-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023858-37.